跳至主要内容
临床试验/NCT01066832
NCT01066832已完成4 期

The Valentines Trial

Eurocor GmbH3 个研究点 分布在 3 个国家目标入组 276 人开始时间: 2010年2月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Eurocor GmbH
入组人数
276
试验地点
3
主要终点
Clinical success at 6-9 month defined as freedom from MACE, death, MI,TLR and stent thrombosis

研究概览

简要总结

The primary objective of this multi-center, international, short term registry is to assess clinical success and efficacy of the paclitaxel eluting balloon treatment for in-stent restenosis at 6-9 months follow up. Clinical success defined as freedom from major adverse cardiac events (MACE: death, myocardial infarction [MI], target lesion revascularization [TLR]) and target vessel revascularization [TVR]) and stent thrombosis, both early and late occurrences will be assessed.

In addition, a cohort of the registry will undergo angiographic follow up at 6-9 months to assess in-stent and in-segment late loss and binary restenosis subsequent to paclitaxel eluting balloon treatment for in-stent restenosis.

A prioi analysis will be comparison of the safety and efficacy of patients presenting with drug-eluting stent in-stent restenosis to bare metal stent in-stent restenosis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients, male or female, > 18 years of age;
  • Patients who present with in-stent restenosis of a previously placed stent documented by coronary angiogram for which re-PCI is planned;
  • The patient has stable or unstable angina, and/or clinical evidence of ischemia (ECG, exercise test, etc.);
  • The target lesion is in a native vessel;
  • Up to two lesions per patient;
  • Target lesion(s) stenosis is > 50%.

排除标准

  • The patient has had an acute myocardial infarction within the last 48 hours;
  • The patient has a co-morbid illness (i.e. any illness likely to limit his/her life expectancy to <12 months);
  • Lesion(s) requiring additional stenting either bare metal or drug eluting (non, bail-out indications);
  • The patient has had previous therapeutic radiation to the target vessel;
  • The patient is unable the take dual antiplatelet therapy for at least 6 months;
  • Patients with three or more lesions with in-stent restenosis requiring angioplasty.

结局指标

主要结局

Clinical success at 6-9 month defined as freedom from MACE, death, MI,TLR and stent thrombosis

时间窗: 6-9 month

次要结局

  • In-stent and in-segment late loss and binary restenosis(6-9 month)

研究者

发起方
Eurocor GmbH
申办方类型
Industry

研究点 (3)

Loading locations...

相似试验